dexrazoxane has been researched along with Disease Models, Animal in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 2 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Abrams, RPM; Bachani, M; Balasubramanian, A; Brimacombe, K; Dorjsuren, D; Eastman, RT; Hall, MD; Jadhav, A; Lee, MH; Li, W; Malik, N; Nath, A; Padmanabhan, R; Simeonov, A; Steiner, JP; Teramoto, T; Yasgar, A; Zakharov, AV | 1 |
| Ding, J; Hu, G; Liu, M; Lu, M; Mei, M; Wang, C; Zhao, F; Zhou, Y | 1 |
| Cai, L; Ji, H; Keller, BB; Leng, J; Yu, H; Zhen, J | 1 |
| Dou, L; Huang, X; Jin, Z; Li, J; Man, Y; Qiu, Q; Ruan, Y; Shen, T; Sun, S; Tang, W; Wang, Q; Yan, M; Yu, X; Zhang, X | 1 |
| Aryal, B; Baxa, U; Bonner, W; Cheng, G; Dickey, JS; Gonzalez, Y; Herman, E; Joseph, J; Kalyanaraman, B; Mason, KP; Mog, S; Nakamura, AJ; Parekh, P; Rao, VA; Redon, CE; Rosen, E; Shacter, E; Zielonka, J | 1 |
| Bongoni, AK; Christen, S; Kamat, P; Khattab, AA; Meier, B; Rieben, R; Vandenberghe, S | 1 |
6 other study(ies) available for dexrazoxane and Disease Models, Animal
| Article | Year |
|---|---|
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Drug Evaluation, Preclinical; High-Throughput Screening Assays; Immunocompetence; Inhibitory Concentration 50; Methacycline; Mice, Inbred C57BL; Protease Inhibitors; Quantitative Structure-Activity Relationship; Small Molecule Libraries; Vero Cells; Zika Virus; Zika Virus Infection | 2020 |
Antioxidant and anti-inflammatory effects of dexrazoxane on dopaminergic neuron degeneration in rodent models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anti-Inflammatory Agents; Antioxidants; Blood-Brain Barrier; Dexrazoxane; Disease Models, Animal; Dopaminergic Neurons; Endoplasmic Reticulum Stress; Inflammation; Male; Mice; Neurodegenerative Diseases; Neuroprotective Agents; Oxidative Stress; Oxidopamine; Parkinson Disease; Pars Compacta; Rats; Rats, Sprague-Dawley | 2019 |
Neonatal murine engineered cardiac tissue toxicology model: Impact of dexrazoxane on doxorubicin induced injury.
Topics: Animals; Animals, Newborn; Cardiotoxicity; Dexrazoxane; Disease Models, Animal; DNA Topoisomerases, Type II; Doxorubicin; Iron Chelating Agents; Metallothionein; Mice; Mice, Transgenic; Myocytes, Cardiac; Reactive Oxygen Species; Tissue Engineering | 2019 |
Dexrazoxane Protects Cardiomyocyte from Doxorubicin-Induced Apoptosis by Modulating miR-17-5p.
Topics: Animals; Apoptosis; Cardiotoxicity; Cell Survival; Dexrazoxane; Disease Models, Animal; Doxorubicin; Male; Mice; Mice, Inbred C57BL; MicroRNAs; Myocytes, Cardiac; Protective Agents; PTEN Phosphohydrolase; Up-Regulation | 2020 |
Mito-tempol and dexrazoxane exhibit cardioprotective and chemotherapeutic effects through specific protein oxidation and autophagy in a syngeneic breast tumor preclinical model.
Topics: Animals; Antioxidants; Autophagy; Breast Neoplasms; Cell Line, Tumor; Dexrazoxane; Disease Models, Animal; Female; Microtubule-Associated Proteins; Mitochondria, Heart; Organophosphorus Compounds; Oxidation-Reduction; Piperidines; Protein Carbonylation; Rats; Rats, Inbred SHR | 2013 |
Dexrazoxane Shows No Protective Effect in the Acute Phase of Reperfusion during Myocardial Infarction in Pigs.
Topics: Acute Disease; Administration, Intravenous; Animals; Chemokine CCL2; Complement C3c; Complement Membrane Attack Complex; Dexrazoxane; Disease Models, Animal; Myocardial Infarction; Myocardial Reperfusion Injury; Myocardium; Necrosis; Platelet Endothelial Cell Adhesion Molecule-1; Reactive Oxygen Species; Risk Factors; Swine; Troponin I; Ventricular Function, Left | 2016 |